A Phase 1, Dose-escalation, Placebo- and Active-Controlled Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1934 and the Effect of Concomitant Proton Pump Inhibitor Administration in Healthy Volunteers
Latest Information Update: 21 May 2022
At a glance
- Drugs Labafenogene marselecobac (Primary) ; SYNB-1618 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; First in man
- Sponsors Synlogic
- 17 May 2022 Status changed from recruiting to completed.
- 20 Sep 2021 Results presented in Synlogic Media Release
- 19 Jul 2021 New trial record